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ABSTRACT
Glycogen synthase kinase (GSK) 3β, which mediates fundamental cellular 
signaling pathways, has emerged as a potential therapeutic target for many types of 
cancer including colorectal cancer (CRC). During mitosis, GSK3β localizes in mitotic 
spindles and centrosomes, however its function is largely unknown. We previously 
demonstrated that translocated promoter region (TPR, a nuclear pore component) 
and dynein (a molecular motor) cooperatively contribute to mitotic spindle formation. 
Such knowledge encouraged us to investigate putative functional interactions among 
GSK3β, TPR, and dynein in the mitotic machinery of CRC cells. Here, we show that 
inhibition of GSK3β attenuated proliferation, induced cell cycle arrest at G2/M phase, 
and increased apoptosis of CRC cells. Morphologically, GSK3β inhibition disrupted 
chromosome segregation, mitotic spindle assembly, and centrosome maturation 
during mitosis, ultimately resulting in mitotic cell death. These changes in CRC cells 
were associated with decreased expression of TPR and dynein, as well as disruption 
of their functional colocalization with GSK3β in mitotic spindles and centrosomes. 
Clinically, we showed that TPR expression was increased in CRC databases and primary 
tumors of CRC patients. Furthermore, TPR expression in SW480 cells xenografted into 
mice was reduced following treatment with GSK3β inhibitors. Together, these results 
indicate that GSK3β sustains steady mitotic processes for proliferation of CRC cells 
via interaction with TPR and dynein, thereby suggesting that the therapeutic effect 
of GSK3β inhibition depends on induction of mitotic catastrophe in CRC cells.  
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INTRODUCTION
Colorectal cancer (CRC) is the third most common 
cancer worldwide, causing over 600,000 deaths per 
year despite recently declining rates for incidence and 
mortality [1, 2]. A large number of CRC patients are 
susceptible to recurrent and metastatic tumors following 
curative surgery, and many undergo adjuvant systemic 
therapies including 5-fluorouracil–based chemotherapy. 
Identification of new therapeutic targets is therefore 
required to decrease CRC-related mortality. Emerging 
potential targets are molecules that act as biological 
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machinery in mitosis, a fundamental prerequisite for 
cancer cell propagation [3–5].
Glycogen synthase kinase-3β (GSK3β), a serine/
threonine protein kinase regulating multiple cell signaling 
pathways, is constitutively active in normal cells. Its activity 
is finely controlled by the differential phosphorylation of 
its serine 9 (S9) residue (pGSK3βS9, inactive state) and 
tyrosine 216 (Y216) residue (pGSK3βY216, active state). 
Depending on its respective primary functions, GSK3β has 
been implicated in glucose intolerance, neurodegenerative 
disorders, chronic inflammatory and immunological 
diseases, and cancer [reviewed in 6–9]; although the various 
roles described for GSK3β in cancer remain complex and 
controversial [reviewed in 8]. Notably, roles for GSK3β 
and microRNAs in epithelial–mesenchymal transition 
and cancer stem cells were reported recently [reviewed in 
10]. Our previous studies found that increased expression 
of total GSK3β and its active fraction (pGSK3βY216) is a 
distinct feature of many cancer types [reviewed in 7, 9, 11] 
including CRC [12–15]. Moreover, we and other groups 
have demonstrated the preferential therapeutic effect of 
GSK3β inhibition against these cancers, underscoring this 
kinase as a promising target in cancer treatment [7–9].
During the multistep process of mitosis, GSK3β 
localizes to the spindle apparatus and centrosomes 
[16, 17]. GSK3β phosphorylates and alters the motility of 
dynein [18], a microtubule minus end-directed molecular 
motor involved in positioning of the mitotic spindle and 
microtubule-organizing centers [19–21]. GSK3β also 
stabilizes bicaudal-D and dynein-interacting complex 
leading to microtubule anchorage at centrosomes [22]. 
A recent study reported the therapeutic effect of GSK3β 
inhibition on cancer via disruption of centrosome 
homeostasis resulting in mitotic catastrophe [23]. 
However, little is known about whether and how GSK3β 
mediates mechanistic processes in the spindle apparatus 
and centrosomes during mitosis in cancer cells. 
The nuclear pore complex (NPC), a cylindrical 
and symmetric microstructure composed of multiple 
copies of up to 30 different proteins termed nucleoporins 
(Nups) (Supplementary Figure 1), is the sole gateway 
for nucleocytoplasmic exchange of macromolecules 
[24–26]. Nups are organized into biochemically stable 
sub-complexes that serve as NPC building blocks 
[27–29]. From the pore center region, a group of Nups 
(called FG Nups for their rich content in phenylalanine-
glycine repeats) extend and retract their intrinsically 
disordered FG repeats to form the permeability barrier 
that bestows selectivity and specificity to the NPC [30]. 
Indeed, using high-speed atomic force microscopy (HS-
AFM), we recently revealed that the native nuclear pore 
inner channel resembles broken cobwebs or brushes 
in HCT116 colon cancer cells [31]. Aside from their 
functions as NPC constituents, we and others also found 
that several Nups participate in cell division and maintain 
centrosomal homeostasis [32, 33]. These studies provide 
new insight into the putative role of certain Nups in the 
process of cancer cell mitosis [25, 34]. Recent evidence 
suggests that the nuclear envelope and nuclear transport 
machinery have emerged as a therapeutic target in 
oncology to restore physiological homeostasis between 
the nucleus and cytoplasm [reviewed in 35]. Translocated 
promoter region (TPR), which normally localizes to the 
nuclear pore basket, is a potential proto-oncogenic Nup 
[36–39] (Supplementary Figure 1). The N terminus of 
TPR undergoes frequent rearrangement with Met, Trk, and 
Raf oncogenes in gastric and thyroid cancers, resulting in 
hyperactive tyrosine kinase fusions [40]. TPR comprises 
a region near the C terminus that is highly enriched in 
aspartic and glutamic acids, as is observed in many histone 
chaperones. Moreover, a proteomic analysis of nascent 
chromatin structures identified TPR as a chromatin-
associated protein [41, 42]. 
We reported that TPR facilitates the biodynamic 
process of mitosis by translocalizing to the spindle apparatus 
and centrosomes, whereby it binds and interacts with the 
MAD1-MAD2 cell cycle checkpoint protein complex 
and dynein/dynactin molecular motor complex [43, 44]. 
Moreover, GSK3β could phosphorylate TPR at S2059 in 
silico [45]. Considering all of this background knowledge 
collectively, we hypothesize that GSK3β may sustain the 
mitotic process in cancer cells by interacting with critical 
mitotic mediators such as TPR and dynein sub-complexes. 
RESULTS
GSK3β inhibition attenuated survival and 
proliferation of CRC cells
To ascertain the role of GSK3β in tumor cell biology, 
we examined the effect of GSK3β inhibition on survival 
and proliferation of CRC cells. Consistent with our previous 
studies [12–15], GSK3β-specific small-molecule inhibitors 
AR-A014418 [46] and SB-216763 [47] reduced the 
proliferation of CRC cells (HCT116, SW480, LoVo, and 
HT-29) compared with the same cells treated with dimethyl 
sulfoxide (DMSO, diluent for inhibitors) (Supplementary 
Figure 2A). This effect was time- and dosage-dependent 
within the reported pharmacological dosage ranges of 
respective inhibitors [46, 47]. The same effect was observed 
in these cancer cell lines following depletion of GSK3β 
expression by treatment with a specific small interfering 
RNA (siRNA), whereby depletion efficiency was confirmed 
by immunoblotting (Supplementary Figure 2B). The 
effect of GSK3β-specific siRNA was compromised by 
co-transfection of the constitutively active mutant form 
of GSK3β (GSK3β S9F-HA; Supplementary Figure 2C). 
These results reconfirmed that CRC cells depend on GSK3β 
expression and activity for proliferation.
Next, we examined whether GSK3β inhibition 
alters the respective cell cycle fractions in CRC cells. 
Figure 1A shows a representative DNA histogram of 
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HCT116 cells after treatment with DMSO, AR-A014418, 
or SB-216763. Analysis by flow cytometry showed that 
treatment of cells with pharmacological GSK3β inhibitors 
at 25 µM increased S-phase, G2/M-phase, and sub-G1 
fractions, while decreasing the G0/G1-phase fraction 
in HCT116 (Figure 1B) and SW480 cells (Figure 1D). 
The same effect was observed following depletion of 
GSK3β expression in HCT116 (Figure 1C) and SW480 
cells (Figure 1E). The results indicated that GSK3β 
inhibition induced cell cycle arrest at S or G2/M phase, 
and apoptosis. This effect was associated with increased 
levels of cyclin-B1 expression and phosphorylation of the 
S10 residue of histone H3 (p-H3S10), which are involved in 
the G2/M phase transition, and cleaved poly [ADP-ribose] 
polymerase 1 (PARP-1), a surrogate marker for apoptosis 
(Figure 1F). Taken together, GSK3β inhibition attenuated 
cell survival and proliferation by inducing cell cycle arrest 
and apoptosis in CRC cells. 
GSK3β colocalizes and interacts with TPR and 
dynein in the centrosome of CRC cells 
The cell cycle arrest induced in cancer cells by GSK3β 
inhibition as shown above (Figure 1) suggests a mechanistic 
role of this kinase in the biodynamic process of mitosis. 
We therefore examined the effects of GSK3β inhibition on 
chromosome segregation and centrosome duplication, two 
critical mechanistic events during mitosis [3, 4].
Here, we visualized centrosomes by immuno-
fluorescence labeling of γ-tubulin, a well-known 
centrosome marker, in HCT116 (Figure 2A) and SW480 
cells (Supplementary Figure 3). We found cells with 
abnormal centrosome number or with abnormal spindles 
after treatment with GSK3β inhibitor (Figure 2A, and 
Supplementary Figure 3) or GSK3β RNAi (Figure 2B) for 
72 h. Treatment with either AR-A014418 or SB-216763 
significantly increased the incidence of cells at interphase 
with multiple nuclei (Figure 2C), as well as those at 
mitotic phase with abnormal chromosome segregation 
and multiple centrosomes (Figure 2D). The numbers of 
cells with abnormal multi-nuclei or abnormal centrosome 
segregation were counted (n = 300 cells, p < 0.0001; 
Figures 2C and 2D). 
To ascertain the dysregulation of centrosomes, 
we further monitored the effect of GSK3β inhibition on 
centrosomes in HCT116 cells by live-imaging analysis of 
cells expressing green fluorescent protein (GFP)-centrin 
2 (another known centrosome marker) fusion protein. 
Following treatment with AR-A014418 and SB-216763 at 
25 µM, a significant number of GFP-centrin 2 repetitively 
moved forth and back until cells underwent mitotic death 
(Supplementary Movie 1 [control], S2 [AR-A014418], S3 
[SB-216763], and S4 [GSK3β RNAi]). These findings allow 
us to hypothesize that GSK3β participates in the mitotic 
process by interacting with the dynein-TPR mitotic mediator 
complex at centrosomes. Immunoprecipitation of whole 
extracts from HCT116 cells synchronized at the M-phase with 
anti-γ-tubulin antibody resulted in co-precipitation of GSK3β, 
TPR, and dynein (Figure 2F, left panels). Consistent with 
immunostaining and live-cell imaging data (Figures 2A, 2B, 
and Supplementary Movies 1–4), treatment with either 
GSK3β inhibitor decreased co-immunoprecipitation of 
TPR and dynein with γ-tubulin (Figure 2F, middle and 
right panels). These results suggest that GSK3β colocalizes 
and potentially works together with TPR and dynein in 
centrosomes during mitosis.
GSK3β inhibition reduced TPR expression and 
altered TPR-dynein centrosomal localization in 
CRC cells
TPR interacts with spindle checkpoints throughout 
the cell cycle. A previous report found that TPR 
overexpression enhanced multinucleation and aneuploidy 
formation. TPR also recruits checkpoint proteins to the 
dynein complex along spindles during mitosis [44]. We 
hypothesized that mitotic abnormalities were also caused 
by disruption of TPR-dynein axis function after GSK3β 
inhibition. To examine spindle polarity defects, we co-
immunostained GSK3β with the spindle marker α-tubulin. 
As predicted, treatment with either GSK3β inhibitor or a 
GSK3β-specific siRNA significantly enhanced spindle 
defects compared with the respective controls (Figure 3A 
and 3B, and Supplementary Figure 4). A previous study 
reported that GSK3β phosphorylates dynein and alters its 
motility via a reduction of Ndel1 binding to intermediate 
chains [18]. Therefore, the results shown above (spindle 
defects) prompted us to investigate whether GSK3β 
affects TPR and dynein [44] in CRC cells during mitosis. 
To examine TPR and dynein protein expression after 
GSK3β inhibition, we performed immunoblotting analysis 
over a time course (from 0 to 72 h) with GSK3β inhibitors 
and GSK3β-specific siRNA, respectively. Notably, TPR 
and dynein were temporally reduced in both HCT116 and 
SW480 cells; however, expression of the TPR binding 
partner MAD1 and dynein binding partner p150 protein 
were not in synchrony with regard to individual inhibitor 
or cell line (Figure 3C). TPR expression was decreased 
when GSK3β expression was depleted in HCT116 and 
SW480 cells (Figure 3D and Supplementary Figure 5). 
Consistent with immunoblotting data, observation with 
confocal laser microscopy revealed that inhibition of 
GSK3β activity induced the mislocalization of dynein 
and TPR in both HCT116 and SW480 cells (Figure 4, and 
Supplementary Figures 6 and 7). 
Next, we explored whether GSK3β biochemically 
interacts with dynein and TPR during the process of 
mitosis. Immunoprecipitation of extract from HCT116 
cells synchronized at the M-phase with an antibody against 
GSK3β co-precipitated dynein and TPR (Figure 5A, left 
panels), while an antibody against TPR co-precipitated 
GSK3β and dynein (Figure 5A, right panels). Treatment 
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Figure 1: GSK3β inhibition altered cell cycle profile and induced apoptosis. (A) Changes in cell cycle fractions of HCT116 
cells after treatment with DMSO (control), 25 µM AR-A014418, or 25 µM SB-216763 for 96 hours. (B) Comparison of DNA histograms 
for each cell cycle fraction of HCT116 cells after treatment with DMSO (control), AR-A014418, or SB-216763, and (C) after treatment 
with non-specific (siCTL) or GSK3β-specific siRNA (siGSK3β). (D) Comparison of DNA histograms for cell cycle fractions of SW480 
cells after treatment with DMSO, AR-A014418, or SB-216763, and (E) after treatment with siCTL or siGSK3β. Data indicate means ± SD 
of three separate experiments. P value < 0.05, statistically significant difference between cells treated with DMSO and either AR-A014418 
or SB-216763. (F) Western blotting analysis for expression of cyclin-B1, histone H3, PARP1 and its cleaved fraction, and phosphorylation 
of histone H3 S10 residue (p-H3S10) in HCT116 and SW480 colon cancer cells treated with DMSO (control), AR-A014418, or SB-216763, 
and after treatment with siCTL or siGSK3β.     
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of cells with GSK3β inhibitors attenuated the biochemical 
association among GSK3β, dynein, and TPR (Figure 5A, 
middle and lower sets of panels). We further investigated 
the signaling cascade position between TPR and GSK3β. 
As predicted, both TPR and pGSK3βY216 (active form) 
localization to the centrosome were remarkably reduced 
after GSK3β inhibition (Supplementary Figure 8A). In 
addition, by using a constitutively active form of GSK3β 
(GSK3β S9F-HA), we found that the number of cells 
with multi-nuclei and abnormal chromosome segregation 
was decreased in HCT116 cells transfected with GSK3β 
S9F-HA compared with cells transfected with empty 
vector following treatment with GSK3β inhibitors 
(Supplementary Figures 8B and 8C). The effects of 
GSK3β S9F-HA transfection were associated with partial 
recovery of TPR expression (Supplementary Figure 8D). 
Together, these results suggest an important role of active 
GSK3β in the centrosome during mitosis. Furthermore, we 
Figure 2: Induction of centrosome abnormalities by GSK3β inhibition. (A) HCT116 cells were treated with DMSO (control), 
or 25 μM AR-A014418 or SB-216763 for 72 hours. Cells were immunostained with anti-GSK3β (green) and anti-γ-tubulin (red) antibodies, 
and nuclei (chromosomes) were counterstained with DAPI (blue) (interphase, upper 12 panels; mitosis, lower 12 panels). Cells with more 
than two centrosomes or with morphologically abnormal centrosomes after treatment with GSK3β inhibitors are shown. (B) Confocal 
microscopic images of mitotic HCT116 cells transfected with control or GSK3β-specific siRNA for 72 hours. Cells were stained with 
anti-GSK3β (green) and anti-γ-tubulin (red) antibodies and counterstained with DAPI (blue). Scale bar = 5 μm. Quantification (relative%) 
of (C) multi-nuclear cells (nucleus more than 1) and (D) chromosome segregation defects with aberrant centrosomes in cells treated with 
DMSO (control), 25 μM AR-A014418, or 25 μM SB-216763. Values are based on three independent experiments, counting 100 mitotic 
cells in each experiment. Mean values with SD are shown. ****P value < 0.0001, statistically significant difference between cells treated with 
DMSO and either of AR-A014418 or SB-216763. (E) Protocol for collecting mitotic HCT116 cells after treatment with GSK3β inhibitor. 
(F) Effects of GSK3β inhibition on associations among γ-tubulin (centrosome marker), GSK3β, TPR and dynein (DIC 74.1) in HCT116 
cells in mitotic phase. HCT116 cells were treated with DMSO (control) and either AR-A014418 or SB-216763 and synchronized at mitotic 
phase. Immunoprecipitates (IP) from extracts of mitotic HCT116 cells with anti-γ-tubulin or nonspecific rabbit IgG were analyzed by 
immunoblotting with indicated antibodies (5% protein extracts were used for input), arrowheads indicate TPR and its isoform.
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Figure 3: GSK3β inhibition induced aberrant spindle polarity and altered expression of TPR and dynein in CRC cells. 
HCT116 cells were immunostained with anti-α-tubulin (spindle apparatus marker; red) and anti-GSK3β (green) antibodies, counterstained 
with DAPI (chromatin; blue) and examined by confocal microscopy. (A) Representative images of HCT116 cells in the process of mitosis 
in control group and groups treated with 25 μM of AR-A014418 or SB-216763. (B) Comparison of images of mitotic HCT116 cells 
transfected with control or GSK3β-specific siRNA for 72 hours. (A, B) Scale bar = 5 µm. (C) Expression of GSK3β, TPR, MAD1, p150, 
and dynein in HCT116 (left panels) and SW480 (right panels) cells treated with 25 μM AR-A014418 or SB-216763 for indicated periods. 
(D) Comparison of immunoblotting indicating levels of expression of GSK3β, TPR, and its associated proteins (MAD1 and dynein) in 
HCT116 (left panels) and SW480 (right panels) cells transfected with control (siCTL) or GSK3β-specific siRNA (siGSK3β) for 72 hours. 
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Figure 4: GSK3β inhibition abolished dynein and TPR centrosomal localization, and caused aneuploidy in cell division. 
HCT116 cells were immunostained with anti-dynein (red) (A, B) or anti-TPR (red) (C, D), and anti-GSK3β (green) (A–D) antibodies and 
examined by confocal laser microscopy. Chromatin was counter-stained with DAPI (blue). Representative images of mitotic HCT116 cells 
treated with DMSO (control) or 25 μM of AR-A014418 or SB-216763 (A, C), or transfected with non-specific (control RNAi) or GSK3β-
specific (GSK3β RNAi) siRNA (B, D). (A–D) Scale bar = 5 µm. 
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found that the depletion of TPR did not alter the expression 
or phosphorylation of GSK3β (Supplementary Figure 9), 
suggesting that TPR functions downstream of GSK3β. To 
further confirm that TPR reduction and mislocalization 
resulted from its ubiquitin-mediated proteasomal 
degradation, we performed qRT-PCR to measure the level 
of TPR mRNA and immunoblotting to measure the level 
of TPR protein following treatment with GSK3β inhibitors 
in the absence and presence of MG132, a proteasome 
inhibitor. As predicted, we detected no significant changes 
in levels of TPR mRNA (Figure 5B), but observed the 
recovery of TPR expression in cells treated with GSK3β 
inhibitors in the presence of MG132 (Figure 5C right 
panels). This result indicates that GSK3β inhibition 
destabilizes TPR by inducing its proteasomal degradation. 
Together, these morphological and biochemical findings 
suggest that GSK3β participates in proper localization 
and function of the mitotic mediators dynein and TPR to 
sustain mitosis for colon cancer cell propagation.
Expression and localization of TPR in human 
CRC tissues and effect of GSK3β inhibition on 
SW480 cell xenografts in mice
Finally, to validate our cellular working model 
(Supplementary Figure 10) in CRC patient samples, 
we examined TPR expression in human CRC tumors. 
Primary samples from ExpO/gene expression profile/
eGWASs were collected from public repositories and 
analyzed [48]. Evaluation of gene expression profiles in 
CRC identified an upregulation of TPR, but not NUP153 
(another nuclear basket protein that binds TPR) [26], in 
CRC patient databases (p < 0.001; Figure 6A left panel). 
This is consistent with the result shown in Figure 5C, as 
well as our previous studies showing higher expression 
and activity of GSK3β in tumors compared with normal 
tissues in CRC patients [12, 15]. Kaplan-Meier analysis 
of TCGA cohorts revealed that TPR overexpression was 
significantly correlated with poorer outcome of colorectal 
Figure 5: GSK3β inhibition induced TPR mislocalization, leading to its proteasomal degradation. (A) HCT116 cells were 
treated with DMSO (control), AR-A014418 (AR), or SB-216763 (SB), and then synchronized at mitotic phase as shown in Figure 3E. 
Immunoprecipitates (IP) from extracts of mitotic HCT116 cells with anti-GSK3β (left panels) and anti-TPR (right panels) antibodies, and 
nonspecific rabbit IgG, were analyzed by immunoblotting with indicated antibodies (arrowheads indicate TPR and its isoform). (B) qRT-
PCR analysis of TPR, DYNEIN, and NUP153 mRNA in HCT116 cells after treatment with DMSO or GSK3β inhibitors (AR-A014418 
and SB-216763) for 48 hours. Data show mean ± SD of three separate experiments. (C) Expression of TPR in HCT116 cells treated with 
DMSO (C), 25 μM AR-A014418 (AR), or SB-216763 (SB) for 72 hours in the presence or absence of MG132 (10 μM) for 8 hours.
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Figure 6: Nucleoporin TPR is upregulated in colon cancers. (A) TPR mRNA expression across normal (N) and tumor (T) tissues 
of colon cancer patients examined from GEO (series GSE9348). Data show mean ± SD (left panel). High TPR expression (mRNA expression 
z-Scores (RNA Seq V2 RSEM)³ mean + 0.1 SD) was associated with poor disease-free survival of colorectal adenocarcinoma patients in 
TCGA cohorts (right panel). (B) Expression and subcellular localization of TPR in the primary tumor of a colon cancer patient. Asterisks 
(enlarged region) indicated pattern of TPR nuclear rim staining occurred exclusively in most cancer cells. (C) Immunohistochemical 
findings of expression and localization of TPR in SW480 xenograft tumors in mice treated with DMSO (control), AR-A014418, or SB-
216763 (both 5 mg/kg body weight) for 5 weeks. Scale bar = 100 μm; H.E., hematoxylin and eosin.
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adenocarcinoma patients (Log-rank test, P = 0.02; 
Figure 6A right panel). Immunohistochemical examination 
of primary tumors from 20 CRC patients (Supplementary 
Table 3) showed higher expression of TPR in nuclei and 
nuclear membranes in cancer cells compared with non-
neoplastic crypt cells (Figure 6B). 
We previously demonstrated the therapeutic effect 
of GSK3β inhibitors (AR-A014418 and SB-216763) 
against SW480 and HT-29 colon cancer cell xenografts in 
athymic mice [14, 15]. Upon examining SW480 xenograft 
tumors by immunohistochemistry, we found lower levels 
of TPR expression in the tumors of mice treated with AR-
A014418 and SB-216763 compared with sham (DMSO)-
treated mice (Figure 6C).
DISCUSSION 
The effect of GSK3β inhibition on survival and 
proliferation of CRC cells observed in this study was 
associated with cell cycle arrest at G2/M phase and the 
induction of apoptosis. As previously reported [16–18, 22], 
our morphological and biochemical analyses showed that 
GSK3β transiently localized and bound to the components 
of centrosomes and mitotic spindles, the key functional 
microstructures driving mitosis, during mitosis of CRC 
cells. Although the efficiency of the two GSK3β inhibitors 
(AR-A014418 and SB-216763) on several cellular 
processes was different, these inhibitors exerted the same 
pharmacological effect impairing the mitotic process of the 
respective colon cancer cell lines. Consequently, our study 
indicate that induction of mitotic catastrophe underpins the 
cancer therapeutic effect of GSK3β inhibition. Suppression 
of cell survival by GSK3β inhibition was consistent with 
our previous studies showing induction of morphologically 
apoptotic bodies/cells, terminal deoxynucleotidyl transferase 
dUTP (2’-deoxyuridine 5’-triphosphate) nick end 
labeling (TUNEL)-positive cells, and ladder-like DNA 
fragmentation, and the suppression of human telomerase 
reverse transcriptase and telomerase-mediated cell 
immortality pathways in colon cancer cells [12–15].
Efficiency of the two GSK3β inhibitors and 
GSK3β-specific siRNA was variable among the colon 
cancer cells examined in this study. Observed differences 
could be attributable to differences in the sensitivities 
or susceptibilities of the respective cancer cells to the 
same inhibitors and/or GSK3β-specific siRNA. The 
biochemical IC50 concentrations of AR-A014418 and SB-
216763 (reported to be 27 nM and 9 nM, respectively) 
were determined by in vitro kinase assays using purified 
enzyme and specific substrate peptides [46, 47]. These 
studies on the development and characterization of the 
above-mentioned GSK3β inhibitors reported the range of 
pharmacological dosages used in the present and previous 
studies [11–15], as well as in other studies (reviewed 
in Ref. No. 7–9). The primary mechanism of action for 
the two pharmacological inhibitors is to block the ATP-
binding domain of GSK3β, but not to directly change 
phosphorylation of its S9 or Y216 residues. Importantly, 
we previously demonstrated that these inhibitors directly 
inhibit the activity (ability) of GSK3β to phosphorylate its 
substrate in colon cancer SW480 and HCT116 cells, which 
are also used in the present study, and that this effect is 
dosage-dependent in the reported pharmacological dosage 
range [13, 15]. Therefore, the effects of these inhibitors on 
cells at dosages used in our present and previous studies 
[11–15] were based on their pharmacological effect 
against cellular GSK3β activity, but not by off-target 
effects against other kinases or side effects. However, it is 
important to confirm the therapeutic effects of these two 
inhibitors are specific for GSK3β activity, but not non-
specific or off-target effects. To achieve this, we tested a 
GSK3β-specific siRNA on colon cancer cells. In many 
cases, the effect of an enzyme largely depends on its 
biological or catalytic activity rather than its amount. Such 
is the case for GSK3β and we previously reported that the 
pharmacological GSK3β inhibitors (AR-A014418 and SB-
216763) inactivate GSK3β in cancer cells within an hour 
after treatment, while the GSK3β-specific siRNA takes 
longer than 48 hours to efficiently, but not completely, 
deplete GSK3β expression in the same cells [13, 15]. 
Therefore, we believe that pharmacological inhibitors 
more quickly inhibit GSK3β activity in cells, leading to 
a stronger biological effect on colon cancer cells than 
treatment with a GSK3β-specific siRNA, as shown in 
Figure 1F and Supplementary Figure 2.
In close relation to the present study, our research 
group recently reported the results of a clinical trial 
for treatment of recurrent glioblastoma patients with 
repurposed GSK3β-inhibiting medicines in combination 
with temozolomide [49]. In this clinical study, we 
observed that GSK3β-inhibiting medicines attenuated cell 
proliferation and invasion of patients’ brain tumors, as 
well as primary tumors in a mouse glioblastoma model. 
This clinical study suggests that GSK3β inhibition may 
also attenuate cell viability and proliferation in primary 
colon cancer cells. Therefore, investigation of the effects 
of GSK3β inhibition on primary CRC cells (e.g. primary 
cultures of tumors from CRC patients and patient-derived 
tumor xenografts) will facilitate therapeutic application in 
CRC patients. 
We previously found an unexpected role of 
NUP358/Ran-binding protein 2 showing that, in addition 
to its primary function as a structural component of NPC 
in cancer cells division, it is also involved in mitotic 
catastrophe in HeLa cells [32]. Subsequently, a recent 
study confirmed its role in mitosis in CRC cells [33], and 
proposed the precision treatment of CRC by repurposing 
vinorelbine, a microtubule-targeting agent approved for 
several cancer types other than CRC. In addition to this 
Nup, we have demonstrated that TPR, a nuclear pore 
basket constituent present in cells at interphase, facilitates 
mitotic processes in cancer cells [43, 44]. To explore the 
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putative molecular mechanism controlling TPR and dynein 
complexes in cellular mitosis, we hereby showed the unique 
finding that mitotic aberration (or catastrophe) induced by 
GSK3β inhibition coincided with impaired interaction 
among TPR, dynein, and GSK3β in mitotic CRC cells. 
Impairment of the control of cell cycle is one of the 
characteristic hallmarks of cancer [50]. This notion has 
prompted the development of cancer therapy targeting 
mitosis, which is central to the cell cycle program [3–5, 51]. 
Early generations of clinically evaluated cancer 
therapeutics included agents targeting microtubule 
dynamics and inhibitors of mitotic kinases such as cyclin-
dependent kinases (CDKs) [51], aurora kinases [52] and 
polo-like kinases [53, 54]. Despite numerous clinical 
trials, the efficacy of these agents has been disappointing 
due to their narrow therapeutic windows in association 
with substantial adverse effects affecting bone marrow, 
nerves, and gastrointestinal tract tissue [reviewed in 3]. 
However, recent evidence supporting the preferential 
dependence of cancer cells on interphase CDKs, including 
CDK4 and CDK6, suggests higher efficiency of a new 
class of agents targeting CDKs [55, 56]. We previously 
demonstrated that GSK3β sustains expression of CDK4, 
CDK6, and cyclin D1, which results in phosphorylation-
dependent inactivation of RB cell cycle regulator, in 
CRC and pancreatic cancer cells [15, 57]. Therefore, the 
disruption of interphase cell cycle procession would also 
underlie the cancer therapeutic effect of GSK3β inhibition. 
While genomic/chromosomal instability is 
recognized as the global genomic hallmark of cancer 
[50], excessive instability renders cancer cells intolerable 
to survival or propagation [58, 59]. Therefore, to relief 
unfavorable effects of the mitotic kinase inhibitors 
discussed above, genomic/chromosomal instability has 
emerged as the attractive cancer therapeutic target in cell 
cycle and mitotic process [reviewed in 3]. Based on this 
knowledge, mitotic mediators controlling centrosome 
biodynamics and mitotic spindle assembly (two critical 
processes for accurate chromosomal alignment that 
ensure genome stability) have become potential targets 
in cancer therapy [60]. As chromosomal instability is 
the representative consequence of aberration in mitotic 
processes, our present study suggests that the disturbance 
of chromosomal segregation, mitotic spindle assembly, 
and centrosome duplication in CRC cells following 
treatment with GSK3β inhibitors may cause excessive 
chromosomal instability that is compatible with the 
therapeutic effect of GSK3β inhibition. 
Our immunofluorescence and live-cell imaging 
results provide the first evidence that GSK3β inhibition 
disrupted TPR and dynein forming a sub-complex in 
centrosomes and facilitated aberrant multi-centrosomes 
formation. Our study thus raises a new notion that 
TPR and dynein interact and participate in promotion 
of mitotic process in CRC cells under the control by 
GSK3β (Supplementary Figure 10). Indeed, GSK3β 
phosphorylates TPR at S2059 in silico [45]. We speculate 
that GSK3β phosphorylation regulates the stability of TPR 
and the transient interaction between TPR and its mitotic 
binding partners such as MAD1, dynein, or Aurora A 
during mitosis (Supplementary Figure 10). Further, our 
work also provides new insights into mechanisms for 
cancer cell mitosis, and reinforces this strategy for cancer 
treatments targeting GSK3β [7]. It is still unclear exactly 
how GSK3β is recruited to the centrosome/spindle pole, 
but this mechanism seems to involve a cascade of events 
and potentially involves dynein motors. 
Finally, we examined the expression of TPR in human 
CRC tumors from the database. Primary samples from ExpO/
gene expression profile/eGWASs were collected from public 
repositories [48]. As predicted, evaluation of gene expression 
profiles in CRC identified an upregulation of TPR in GEO 
database (P < 0.001, Figure 6A). Collectively, this study sheds 
light on a novel mitotic function of GSK3β in the regulation 
of TPR-dynein mediated centrosome homeostasis, which 
may facilitate the discovery of new treatment regimens for 
cancer targeting mitosis. Future clinical investigations should 
explore how GSK3β-TPR contributes to carcinogenesis.
MATERIALS AND METHODS
Cell culture
Human colon cancer HCT116, SW480, LoVo, and 
HT-29 cells were obtained from American Type Culture 
Collection. Cells were propagated in Dulbecco’s Modified 
Eagle’s Medium (DMEM) supplemented with 10% (v/v) 
fetal bovine serum (Life Technologies) and 50 U/mL 
penicillin-streptomycin (Nacalai Tesque). Cells were 
cultured in a humidified incubator at 37° C with 5% CO2. 
Cells were synchronized in S-phase by thymidine block 
using 2 mM thymidine (Figure 2E) [43, 44].
Cell viability assay
Colon cancer cells were seeded in 96-well culture 
plates at a density of 3,000 cells per well. Cells were then 
treated with DMSO or GSK3β inhibitors (AR-A014418 
[46] or SB-216763 [47]) (Sigma-Aldrich) at the indicated 
concentrations. At each time point (0, 12, 24, 48, and 
72 hours), cell viability was determined using a WST-8 
assay kit (Cell Counting Kit-8, Dojindo Laboratories). 
Optical density was measured using a microplate reader 
(Model 680, BIO-RAD) at 450 nm, and the results 
are shown as the mean of optical density and standard 
deviations of each four-well set.
Plasmid, RNA interference, and treatment with 
GSK3β inhibitors 
The expression plasmid for constitutively active 
GSK3β tagged with an HA epitope (pCI-GSK3β S9F-HA) 
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was constructed by inserting a GSK3β cDNA fragment 
amplified using a set of primers (Supplementary Table 1) 
into the pCI vector (Promega), and then performing an amino 
acid substitution of the S9 residue to phenylalanine (F) by 
mutagenesis with a set of primers listed in Supplementary 
Table 1. Small interfering (si)RNA duplexes targeting 
GSK3β (5ʹ-AUCUAGCUUUCUCAUGAUCUGGAGC-3ʹ), 
TPR-specific siRNA (sc-45343), and control siRNA (sc-
37007) were purchased from Santa Cruz Biotechnology. 
Plasmid and siRNA were transfected using Lipofectamine 
2000 (Invitrogen) according to the manufacturer’s protocol 
[43, 44]. HCT116 and SW480 cells were plated onto 12- 
or 6-well tissue culture plates at a density of 1 × 105 cells 
per well. Cells were transfected with siRNA and observed 
72 hours after transfection. To examine the effect of inhibition 
of GSK3β activity, cells were treated with 25 µM AR-
A014418 [46] or 25 µM SB-216763 [47] (Sigma-Aldrich) 
and collected at the indicated periods. 
Immunocytochemistry, confocal microscopy, and 
live-cell imaging 
This study used antibodies against GSK3β (32391, 
Abcam) and TPR (sc-101294, Santa Cruz Biotechnology). 
Monoclonal antibodies against dynein (D5167, clone 
74.1), α-tubulin (DM1A), and γ-tubulin were from Sigma-
Aldrich. Secondary antibodies (Alexa Fluor- or Rhodamine-
conjugated) were from Molecular Probes (Life Technologies). 
For observation by confocal microscopy, M-phase–
synchronized HCT116 cells on coverslips were washed 
in phosphate-buffered saline (PBS) and fixed for 10 
min in 4% paraformaldehyde in PBS. Cells were then 
permeabilized with 0.3% Triton X-100 in PBS for 10 
minutes at room temperature. Cells were then incubated 
with each of the indicated primary antibodies for 3 
hours, washed three times, and incubated with Alexa 
Fluor-conjugated secondary antibody for 2 hours. After 
washing with PBS, cells were incubated with the second 
primary antibody for 3 hours, followed by incubation 
with Rhodamine-conjugated secondary antibody for 2 
hours for double immunostaining. Cells were mounted 
onto coverslips with ProLong Gold Antifade reagent with 
4′,6-diamidino-2-phenylindole (DAPI; Invitrogen). 
Real-time live-cell imaging was performed using 
HCT116 GFP-centrin and SW480 GFP-TPR stable cells 
treated with DMSO, GSK3β inhibitor, or GSK3β siRNA. 
Images were acquired 24 and 48 hours after treatment 
using an Olympus FV10i-LIV laser-scanning confocal 
microscope with a 60X PlanApo/1.45NA DIC objective.
Immunoprecipitation and Western blotting 
Procedures used for immunoprecipitation and 
Western blotting were described previously [32, 43]. 
Briefly, mitotic HCT116 cells were collected, washed with 
PBS, and lysed in 1 mL of cold lysis buffer containing 
protease inhibitor mixture. Lysates were centrifuged for 30 
minutes at 4° C at 14,000 × g. The resultant supernatants 
were pre-cleared with 50 µL of protein A/G beads slurry 
(Santa Cruz Biotechnology), mixed with 10 µL of various 
antibodies (as specified), and incubated for 2 hours at 4° C 
with rocking. Beads were then washed five times with 
500 µL of lysis buffer. After the last wash, 50 µL of 1× 
sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) blue loading buffer (New England Biolabs) 
was added to the bead pellet and heated for 10 minutes 
at 95° C before loading. Signals were detected with an 
enhanced chemiluminescence system (GE Healthcare,) 
and quantified using a LAS-4000 image analyzer (Fuji 
Film) according to the manufacturer’s specifications. 
For conventional Western blotting analysis of 
cells at various conditions, we used the same antibodies 
described above for immunofluorescence staining and 
immunoprecipitation. In addition, we also used antibodies 
against GSK3α and β (05-412, Millipore), α-dynactin 
p150 subunit (612709, BD Biosciences), cyclin B1 
(4138P, Cell Signaling), histone H3 (H3; 07-690, 
Millipore), H3 phosphorylated in its S10 residue (p-H3S10; 
06-570, Upstate), PARP1 (sc-7150, Santa Cruz), MAD1 
(sc-47746, Santa Cruz), β-actin (sc-47778, Santa Cruz), 
Y216-phosphorylated GSK3β (pGSK3βY216; 612312, BD 
Biosciences), S9-phosphorylated pGSK3βS9 (9336, Cell 
Signaling), and HA-tag (AM1008a, Abgent).
Cell cycle profile analysis
Fluorescence-activated cell sorting (FACS) analysis 
was performed as described previously [32, 43]. Briefly, 
72 hours after treatment with DMSO, 25 μM AR-
A014418, or 25 μM SB-216763, HCT116 cells were 
trypsinized, washed twice with PBS, and fixed in 70% 
ethanol at –20° C overnight. Fixed cells were resuspended 
in PBS containing 50 µg/mL RNase A (Nacalai Tesque) 
and 50 µg/mL propidium iodide (PI) (Sigma-Aldrich). 
Cellular DNA content was analyzed using a FACS Canto 
II with FACS Diva software (BD Bioscience).
cDNA preparation and quantitative real-time 
RT-PCR assay
RNA was prepared using a NucleoSpin RNA isolation 
kit (Macherey–Nagel), and cDNA was synthesized using 
the ThermoScript RT-PCR system (Takara). Quantitative 
real time RT-PCR was performed using a Thermal Cycler 
Dice Real Time System with SYBR Premix Ex Taq II 
(Takara). Relative mRNA expression levels of target 
genes were calculated using glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) as an internal control. Primers 
are listed in Supplementary Table 2.
Patients and tissue specimens
We analyzed the primary tumor tissues of 20 CRC 
patients undergoing surgery at our University Hospital 
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(Supplementary Table 3). Written informed consent was 
obtained from each patient in accordance with institutional 
guidelines. Our investigation was conducted in accordance 
with ethical standards and the Declaration of Helsinki, and 
according to national and international guidelines, after 
approval by our Institutional Review Board.
Human CRC xenograft tumors in mice treated 
with GSK3β inhibitor
In our previous study, we demonstrated the efficacy 
of GSK3β inhibitors (AR-A014418 and SB-216763) against 
SW480 cell xenografts in athymic mice [14]. For histological 
and immunohistochemical examination, representative sections 
were prepared from archived tissue blocks of formalin-fixed 
and paraffin-embedded tumors of rodents treated with DMSO 
(control), AR-A014418 (5 mg/kg body weight), or SB-216763 
(5 mg/kg body weight) for 5 weeks.  
Histological and immunohistochemical 
examination
Respective paraffin sections of CRC tumors and 
xenografts were histologically examined by hematoxylin 
and eosin staining. Expression of TPR in tumor tissues was 
immunohistochemically examined using an avidin-biotin-
peroxidase complex method described in our previous studies 
[15]. Representative paraffin sections placed on silanized 
slides (Dako) were treated by microwaving in citrate buffer to 
unmask antigens, incubation with 0.3% H2O2 in methanol, and 
subsequent incubation with 10% normal goat serum to block 
non-specific immunohistochemical reactions. Pretreated tissue 
sections were incubated with a rabbit polyclonal antibody 
against TPR (diluted 1:100; Santa Cruz). After incubation 
with the antibody, sections were incubated with biotinylated 
goat anti-rabbit IgG (Vector Laboratories) diluted 1:200 in 
PBS containing 10% normal goat serum. For mouse xenograft 
tumors, final concentrations of 1% bovine serum albumin and 
10% normal mouse serum (DakoCytomation) were added to 
the diluent of anti-rabbit IgG to prevent cross-reaction with 
endogenous mouse IgG [14, 15].
Bioinformatics and data analysis
TPR mRNA expression in CRC was obtained from 
GEO (Accession No. GSE9348, https://www.ncbi.nlm.
nih.gov/geo/GSE9348). Survival curves from The Cancer 
Genome Atlas (TCGA, http://cancergenome.nih.gov/) 
were obtained through cBio Cancer Genomics Portal 
(http://www.cbioportal.org/). All bioinformatics data were 
accessed and analyzed accordingly [61] .
Statistical analysis
Statistical analysis was performed using GraphPad 
PRISM 7. Data are shown as means ± standard deviation 
(SD). Comparisons between respective groups were 
determined using an unpaired T-test or two-way ANOVA. 
P values < 0.05 were considered statistically significant.
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